Atherosclerosis - Pipeline Review, H2 2015 Summary Global Markets Direct s, Atherosclerosis - Pipeline Review, H2 2015, provides an overview of the Atherosclerosiss therapeutic pipeline.

[USPRwire, Wed Oct 25 2017] This report provides comprehensive information on the therapeutic development for Atherosclerosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Atherosclerosis and special features on late-stage and discontinued projects. Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Atherosclerosis - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Atherosclerosis and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Atherosclerosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Atherosclerosis pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Atherosclerosis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Atherosclerosis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Browse Complete Report with TOC
To Get Sample Copy of Report visit
Table of Contents
Table of Contents 2

List of Tables 7

List of Figures 8

Introduction 9

Global Markets Direct Report Coverage 9

Atherosclerosis Overview 10

Therapeutics Development 11

Pipeline Products for Atherosclerosis - Overview 11

Pipeline Products for Atherosclerosis - Comparative Analysis 12

Atherosclerosis - Therapeutics under Development by Companies 13

Atherosclerosis - Therapeutics under Investigation by Universities/Institutes 16

Atherosclerosis - Pipeline Products Glance 18

Late Stage Products 18

Clinical Stage Products 19

Early Stage Products 20

Atherosclerosis - Products under Development by Companies 21

Atherosclerosis - Products under Investigation by Universities/Institutes 24

Atherosclerosis - Companies Involved in Therapeutics Development 26

Ache Laboratorios Farmaceuticos S/A 26

advanceCor GmbH 27


Arisaph Pharmaceuticals, Inc. 29

Artery Therapeutics, Inc. 30

AstraZeneca Plc 31

Athera Biotechnologies AB 32

AtheroNova Inc. 33

Bayer AG 34

Campus Technologies Freiburg GmbH 35

Cardax Pharmaceuticals, Inc. 36

Cerenis Therapeutics Holding SA 37

ChemoCentryx, Inc. 38

CohBar, Inc. 39

Daiichi Sankyo Company, Limited 40

DoNatur GmbH 41

Dybly AG 42

Exicure, Inc. 43

F. Hoffmann-La Roche Ltd. 44

GenKyoTex S.A. 45

Gilead Sciences, Inc. 46

Jenrin Discovery, Inc. 47

Johnson & Johnson 48

KineMed, Inc. 49

Kowa Company, Ltd. 50

La Jolla Pharmaceutical Company 51

Lead Discovery Center GmbH 52

Merck & Co., Inc. 53

MI.TO. Technology S.r.L. 54

Omeros Corporation 55

OPKO Health, Inc. 56

Otsuka Holdings Co., Ltd. 57

Provid Pharmaceuticals, Inc. 58

Resverlogix Corp. 59

The Medicines Company 60

Therapix Biosciences Ltd 61

Tolerys SA 62

Vascular Biogenics Ltd. 63

Vericel Corporation 64

Virocan Therapeutics Private Limited 65

Vitae Pharmaceuticals, Inc. 66

Atherosclerosis - Therapeutics Assessment 67

Assessment by Monotherapy Products 67

Assessment by Combination Products 68

Assessment by Target 69

Assessment by Mechanism of Action 73

Assessment by Route of Administration 76

Assessment by Molecule Type 78

Drug Profiles 80

6860766 - Drug Profile 80

AEM-28 - Drug Profile 81

AG-01 - Drug Profile 82

AHRO-001 - Drug Profile 83

AHRO-002 - Drug Profile 85

AHRO-003 - Drug Profile 86

AM-0010 - Drug Profile 87

AmVidcm-009 - Drug Profile 88

anacetrapib - Drug Profile 89

Annexin A-5 - Drug Profile 91

apabetalone - Drug Profile 93

ARI-1778 - Drug Profile 96

Artpep-2 - Drug Profile 97

ATH-03 - Drug Profile 98

ATH-04 - Drug Profile 99

ATH-05 - Drug Profile 100

ATH-06 - Drug Profile 101

AZ-876 - Drug Profile 102

BAY-606583 - Drug Profile 103

BSN-272 - Drug Profile 104

CCX-771 - Drug Profile 105

CDX-085 - Drug Profile 106

Cell Therapy for Atherosclerosis - Drug Profile 108

Cellular Immunotherapy for Atherosclerosis - Drug Profile 109

CER-209 - Drug Profile 110

CM-7 - Drug Profile 111

COR-2 - Drug Profile 112

D-4F - Drug Profile 113

DIAS-2 - Drug Profile 114

Drug for Atherosclerosis - Drug Profile 115

Drugs to Activate TLR3 for Atherosclerosis - Drug Profile 116

Drugs to Antagonize NMDA Receptor for Atherosclerosis - Drug Profile 117

DYB-186 - Drug Profile 118

EP-80317 - Drug Profile 119

FX-5A - Drug Profile 120

Gene Therapy for Arteriosclerosis and Endothelial Dysfunction - Drug Profile 121

Gene Therapy to Activate Interleukin 10 for Atherosclerosis - Drug Profile 122

Gene Therapy to Target miR-145 for Atherosclerosis - Drug Profile 123

GKT-831 - Drug Profile 124

GYY-4137 - Drug Profile 125

Humanin - Drug Profile 127

INV-88 - Drug Profile 129

ISIS-APOARx - Drug Profile 130

ITP-01 - Drug Profile 131

ixmyelocel-T - Drug Profile 132

JD-2000 Series - Drug Profile 135

JD-5000 Series - Drug Profile 136

JD-6000 Series - Drug Profile 137

K-312 - Drug Profile 138

K-877 - Drug Profile 139

KM-011 - Drug Profile 141

KRP-206 - Drug Profile 142

leucine + niacin - Drug Profile 143

LJPC-6417 - Drug Profile 144

LPC-01 - Drug Profile 145

MCS-18 - Drug Profile 146

MDCO-216 - Drug Profile 148

melittin - Drug Profile 150

Read More

About Us:
iData Insights which operates under Precision Research and Consulting Private Limited is a leading market research information aggregator and marketing research consulting firm. We conduct both primary and secondary research. Our work does not end with research it is also involved in distributing reports for different companies . We provide actionable recommendations and provide our expertise for business success today and tomorrow. It is our goal to be a partner to our clients in the exploration and discovery, and then be their guide in the implementation of changes that will make a difference to their bottom line.
iData Insights
Tel: 1-866-237-2965

About iData Insights
We work around the clock until our clients are completely satisfied with their promised results. It is our mission to provide timely services coupled with acute client care to create a long-lasting relationship with you. We deliver on our promise to provide results that are essential to the success of your company. We believe that by doing so, we will earn the trust of our clients for future project.

Company: iData Insights
Contact Name:
Contact Email:
Contact Phone: 18662372965

Visit website »